Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience
…, JC Kamp, A Breithecker, J Fuge… - European …, 2017 - Eur Respiratory Soc
Balloon pulmonary angioplasty (BPA) is an emerging treatment for patients with inoperable
chronic thromboembolic pulmonary hypertension (CTEPH). We report on a prospective …
chronic thromboembolic pulmonary hypertension (CTEPH). We report on a prospective …
[HTML][HTML] C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
I Pink, D Raupach, J Fuge, RP Vonberg, MM Hoeper… - Infection, 2021 - Springer
Purpose Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus
2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID…
2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID…
Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction
MM Hoeper, K Meyer, J Rademacher, J Fuge, T Welte… - JACC: Heart Failure, 2016 - jacc.org
Objectives : This study sought to investigate the prognostic importance of a low diffusion
capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of …
capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of …
[HTML][HTML] Anti-IL-5 therapy in patients with severe eosinophilic asthma–clinical efficacy and possible criteria for treatment response
N Drick, B Seeliger, T Welte, J Fuge… - BMC pulmonary medicine, 2018 - Springer
Background Interleukin-5 (IL-5) antibodies represent a promising therapeutic option for patients
with severe eosinophilic asthma. To date, no official treatment response criteria exist. In …
with severe eosinophilic asthma. To date, no official treatment response criteria exist. In …
[HTML][HTML] Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
T Kramm, H Wilkens, J Fuge, HJ Schäfers… - Clinical Research in …, 2018 - Springer
Background The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) is
unknown. Previous studies from the United Kingdom and Spain have reported incidence …
unknown. Previous studies from the United Kingdom and Spain have reported incidence …
[HTML][HTML] COVID-19 in lung transplant recipients—Risk prediction and outcomes
JC Kamp, JB Hinrichs, J Fuge, R Ewen, J Gottlieb - PloS one, 2021 - journals.plos.org
Patients after lung transplantation are at risk for life-threatening infections. Recently, several
publications on COVID-19 outcomes in this patient population appeared, but knowledge on …
publications on COVID-19 outcomes in this patient population appeared, but knowledge on …
Multiple sclerosis registries in Europe–results of a systematic survey
…, D Eskic, D Ford, T Friede, J Fuge… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: Identification of MS registries and databases that are currently in use in Europe
as well as a detailed knowledge of their content and structure is important in order to …
as well as a detailed knowledge of their content and structure is important in order to …
[HTML][HTML] Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension
KM Olsson, T Meltendorf, J Fuge, JC Kamp… - Frontiers in …, 2021 - frontiersin.org
Objective: Mental health may affect the quality of life (QoL) in patients with pulmonary arterial
hypertension (PAH). However, mental disorders have not been systematically assessed in …
hypertension (PAH). However, mental disorders have not been systematically assessed in …
[HTML][HTML] Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension
H Gall, A Yogeswaran, J Fuge, N Sommer… - …, 2021 - thelancet.com
Background Currently an echocardiographic threshold for the tricuspid regurgitation
gradient (TRG) of > 31 mmHg is recommended for screening for pulmonary hypertension (PH). …
gradient (TRG) of > 31 mmHg is recommended for screening for pulmonary hypertension (PH). …
Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma
N Drick, K Milger, B Seeliger, J Fuge… - Journal of asthma …, 2020 - Taylor & Francis
Background Anti-IL-5 antibodies represent an established therapy for severe eosinophilic
asthma (SEA), but some patients show inadequate response. The objective of this study was …
asthma (SEA), but some patients show inadequate response. The objective of this study was …